NDTV Profit on MSN
Lupin Target Price Cut By Systematix After Q4 Results — Should You Buy, Sell Or Hold?
The near-term earnings growth may be a challenge for Lupin as they should see impact of competition in their largest ...
As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO. Formerly the ...
Real world pharmacovigilance study of FDA adverse event reporting system events for Spiriva Respimat
Abstract Background: Spiriva Respimat (tiotropium bromide) is a first-line therapy for chronic obstructive pulmonary disease (COPD) and asthma, prescribed to millions worldwide. However, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results